Merck KGaA (FRA:MRK) Given a €108.00 Price Target at Warburg Research
Warburg Research set a €108.00 ($121.35) price objective on Merck KGaA (FRA:MRK) in a research note released on Wednesday morning, Borsen Zeitung reports. The firm currently has a neutral rating on the healthcare company’s stock.
MRK has been the subject of a number of other research reports. Kepler Capital Markets set a €122.00 ($137.08) price objective on Merck KGaA and gave the company a sell rating in a research note on Wednesday, July 1st. Barclays set a €90.00 ($101.12) price target on shares of Merck KGaA and gave the company a sell rating in a research report on Wednesday, June 3rd. Independent Research set a €122.00 ($137.08) price objective on shares of Merck KGaA and gave the company a buy rating in a research report on Friday, May 15th. Sanford C. Bernstein set a €115.00 ($129.21) price objective on shares of Merck KGaA and gave the company a neutral rating in a research note on Monday, June 8th. Finally, Goldman Sachs Group set a €94.00 ($105.62) target price on Merck KGaA and gave the stock a sell rating in a research note on Tuesday, July 28th. Three investment analysts have rated the stock with a sell rating, nine have given a hold rating and three have given a buy rating to the stock. The stock presently has an average rating of Hold and an average price target of €108.64 ($122.07).
FRA MRK opened at €108.05 ($121.40) on Wednesday. Merck KGaA has a 1-year low of €76.60 ($86.07) and a 1-year high of €115.00 ($129.21). The stock has a 50-day moving average of €107.71 and a 200-day moving average of €106.94.
MERCK Kommanditgesellschaft auf Aktien operates in the healthcare, life science, and performance materials sectors worldwide. It offers prescription medicines to treat cancer, multiple sclerosis, infertility, growth deficiencies, type 2 diabetes, cardiovascular and thyroid diseases, as well as squamous cell carcinoma of the head and neck; diagnostics and prescription drugs for allergen immunotherapy; and fertility treatments.
Featured Article: Do equity income investments outperform growth and income investments?
Receive News & Ratings for Merck KGaA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck KGaA and related companies with MarketBeat.com's FREE daily email newsletter.